• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

作者信息

Rodrigues A D

机构信息

Drug Metabolism Department, Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

Biochem Pharmacol. 1999 Mar 1;57(5):465-80. doi: 10.1016/s0006-2952(98)00268-8.

DOI:10.1016/s0006-2952(98)00268-8
PMID:9952310
Abstract

With the increased availability of human liver tissue, recombinant (cDNA-expressed) cytochrome P450 proteins (rCYPs), and knowledge of the human CYP pool (e.g. immunoquantitated levels of each CYP form in native liver microsomes), it is now possible to carry out in vitro "CYP reaction phenotyping" in an integrated manner. Reaction phenotyping allows one to identify which CYP form(s) is (are) involved in the metabolism of a given drug, using a combination of data obtained with native human liver microsomes and rCYP proteins. The following describes how one can attempt to integrate such data. A total of ten drugs are included in the analysis, represented by twelve reactions (six hydroxylations, two O-demethylations, one N-demethylation, one O-deethylation, and two sulfoxidations) that are largely catalyzed (> or =20%) by various combinations of CYPs (CYP3A4, CYP2C9, CYP1A2, and CYP2D6), and characterized by a wide range of apparent Km values (12-820 microM). Briefly, reaction rates measured with individual rCYPs are normalized with respect to the nominal specific content of the corresponding CYP in native human liver microsomes. In turn, the normalized rates for each rCYP are summed, yielding a "total normalized rate" (TNR), and the normalized rate for each rCYP is expressed as a percent of the TNR (% TNR). Finally, % TNR is related to inhibition (percent inhibition in the presence of CYP form selective chemical inhibitors; % I) and univariate regression analysis (r > or = 0.63; P < or = 0.05; N > or = 10 different livers) data obtained with native human liver microsomes. Therefore, the reaction phenotype of a drug is assigned by integrating all three data sets (r, % TNR, and % I).

摘要

相似文献

1
Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.
Biochem Pharmacol. 1999 Mar 1;57(5):465-80. doi: 10.1016/s0006-2952(98)00268-8.
2
[O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.人肝微粒体中[O-甲基14C]萘普生O-脱甲基酶活性:细胞色素P4501A2和P4502C9/10参与的证据
Drug Metab Dispos. 1996 Jan;24(1):126-36.
3
Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms.人肝微粒体细胞色素P450同工酶对扎来普隆的代谢
Xenobiotica. 1998 Apr;28(4):337-48. doi: 10.1080/004982598239452.
4
Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.人肝微粒体中参与西酞普兰N-去甲基化的细胞色素P450同工酶的鉴定。
J Pharmacol Exp Ther. 1997 Feb;280(2):927-33.
5
Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.鉴定CYP3A4为人肝微粒体中催化米非司酮(RU 486)氧化的主要酶。
Biochem Pharmacol. 1996 Sep 13;52(5):753-61. doi: 10.1016/0006-2952(96)00357-7.
6
Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.对硫磷在人肝脏中的生物转化:CYP3A4的参与及其在微粒体对硫磷氧化过程中的失活
J Pharmacol Exp Ther. 1997 Feb;280(2):966-73.
7
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.细胞色素P450抑制剂对人及大鼠肝微粒体中探针底物的差异选择性。
Br J Clin Pharmacol. 1998 Feb;45(2):107-14. doi: 10.1046/j.1365-2125.1998.00679.x.
8
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.参与西地那非N-去甲基化的细胞色素P450酶的鉴定。
Br J Clin Pharmacol. 2001 Mar;51(3):239-48. doi: 10.1046/j.1365-2125.2001.00318.x.
9
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.细胞色素P450(CYP)含量与从cDNA表达的CYPs到人类肝微粒体的相对活性缩放方法的比较:辅助蛋白比例作为方法间差异的来源
Drug Metab Dispos. 2000 Dec;28(12):1493-504.
10
Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.克拉霉素在人肝微粒体存在下的氧化代谢。细胞色素P4503A(CYP3A)亚家族起主要作用。
Drug Metab Dispos. 1997 May;25(5):623-30.

引用本文的文献

1
A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models.体外细胞模型在药物相互作用预测和安全性评估新前沿的综述
Pharmaceutics. 2025 Jun 6;17(6):747. doi: 10.3390/pharmaceutics17060747.
2
Metabolic activation and cytotoxicity of carvedilol mediated by cytochrome P450s in vitro and in vivo.细胞色素P450s介导的卡维地洛在体外和体内的代谢活化及细胞毒性
Arch Toxicol. 2025 Jul;99(7):2855-2875. doi: 10.1007/s00204-025-04054-8. Epub 2025 May 17.
3
Assessing Drug-Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption.
使用基于生理学的药代动力学建模(PBPK)方法结合半机制吸收评估BCS 2类化合物BI 730357(维甲酸相关孤儿受体γ拮抗剂,贝武罗根)的药物相互作用和食物效应。
Pharmaceutics. 2025 Mar 1;17(3):314. doi: 10.3390/pharmaceutics17030314.
4
In vitro and In vivo Drug Metabolism Analysis of BPI-460372 - A Covalent TEAD1/3/4 Inhibitor.BPI-460372(一种共价TEAD1/3/4抑制剂)的体外和体内药物代谢分析
Curr Drug Metab. 2025 Feb 11;25(10):754-68. doi: 10.2174/0113892002351556250123105344.
5
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment.一种基于生理学的定量系统药理学模型,用于从机制上理解对阿格列汀的反应及其在肾功能损害患者中的应用。
J Pharmacokinet Pharmacodyn. 2025 Jan 16;52(1):13. doi: 10.1007/s10928-025-09961-y.
6
Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline.个体 P450 物种功能特性的非加和性及其在酒精摄入对氯胺酮和阿米替林代谢影响中的表现。
Biochem Pharmacol. 2024 Dec;230(Pt 1):116569. doi: 10.1016/j.bcp.2024.116569. Epub 2024 Oct 10.
7
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?生理药代动力学(PBPK)建模:胃肠道中细胞色素P450 3A4(CYP3A4)表达在准确预测首过代谢中起什么作用?
CPT Pharmacometrics Syst Pharmacol. 2025 Jan;14(1):130-141. doi: 10.1002/psp4.13249. Epub 2024 Oct 2.
8
Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population.基于生理学的泮托拉唑药代动力学模型研究,评估 CYP2C19 遗传变异和肥胖在儿科人群中的作用。
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1394-1408. doi: 10.1002/psp4.13167. Epub 2024 Jun 4.
9
A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment.CYP 介导的药物相互作用综述:机制与体外药物相互作用评估。
Biomolecules. 2024 Jan 12;14(1):99. doi: 10.3390/biom14010099.
10
Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.基于生理学的药代动力学(PBPK)模型预测不同 CYP2C9 基因型人群中厄贝沙坦的药代动力学。
Arch Pharm Res. 2023 Dec;46(11-12):939-953. doi: 10.1007/s12272-023-01472-z. Epub 2023 Dec 8.